• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CSL 2.48% $277.01

CSL LIMITED - Announcements

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus... CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

CSL CSL Shareholders Pack 201906/09/19
CSL Appendix 4G06/09/19
CSL Notice of 2020 Dividend and AGM Dates06/09/19
CSL CSL Notice of 2019 Annual General Meeting06/09/19
CSL CSL Annual Report 2018/1906/09/19
CSL Appendix 3B12/03/19
CSL Change of Director's Interest Notice21/02/19
CSL Update - Dividend/Distribution - CSL20/02/19
CSL Appendix 3B19/02/19
CSL Dividend/Distribution - CSL13/02/19
CSL Half Year Results Analyst PresentationPRICE SENSITIVE13/02/19
CSL Appendix 4D and Half Year AccountsPRICE SENSITIVE13/02/19
CSL Notice of Investor/Analyst Briefing - Half Year Results 201906/02/19
CSL Appendix 3B29/01/19
CSL 2019 JP Morgan Healthcare Conference10/01/19
CSL CSL R&D Investor BriefingPRICE SENSITIVE05/12/18
CSL Notice of Research & Development Investor Briefing30/11/18
CSL Becoming a substantial holder05/11/18
CSL Change of Director's Interest Notice01/11/18
CSL Final Director's Interest Notice22/10/18
CSL Final Director's Interest Notice22/10/18
CSL Initial Director's Interest Notice22/10/18
CSL Change of Director's Interest Notice19/10/18
CSL Results of Meeting17/10/18
CSL CSL Chairmans Address and CEOs Presentation17/10/18
CSL Appendix 3B25/09/18
CSL Change of Director's Interest Notice21/09/18
CSL Appendix 4G - Key to Disclosures14/09/18
CSL CSL Annual Report to shareholders14/09/18
CSL Notice of Annual General Meeting/Proxy Form14/09/18
CSL Change of Director's Interest Notice07/09/18
CSL Appendix 3B04/09/18
CSL Change of Director's Interest Notice27/08/18
CSL Notice of Annual General Meeting24/08/18
CSL Change of Director's Interest Notice17/08/18
CSL Full Year Results Presentation15/08/18
CSL Full Year Results AnnouncementPRICE SENSITIVE15/08/18
CSL Dividend/Distribution - CSL15/08/18
CSL Full Year Statutory AccountsPRICE SENSITIVE15/08/18
CSL Notice of Investor and Analyst Briefing 2018 FY Results08/08/18
CSL Appendix 3B03/07/18
CSL Appendix 3B22/05/18
CSL CSL Lifts Profit GuidancePRICE SENSITIVE18/05/18
CSL Change of Director's Interest Notice10/05/18
CSL Appointment of Company Secretary19/04/18
CSL Appendix 3B20/03/18
CSL Appendix 3B27/02/18
CSL Change of Director's Interest Notice16/02/18
CSL Initial Director's Interest Notice16/02/18
CSL Initial Director's Interest Notice16/02/18
CSL Half Year Results Analyst Presentation14/02/18
CSL Dividend/Distribution - CSL14/02/18
CSL Appendix 4D and Half Year AccountsPRICE SENSITIVE14/02/18
CSL Notice of Investor/Analyst Briefing - 2018 Half Year Results06/02/18
CSL Company Secretary Appointment/Resignation21/12/17
CSL CSL Appoints New Directors13/12/17
CSL Appendix 3B05/12/17
CSL R&D Investor Briefing05/12/17
CSL PGC: Acquisition of Immunohaematology BusinessPRICE SENSITIVE01/12/17
CSL Notice of Research & Development Investor Briefing30/11/17
CSL Appendix 3B14/11/17
CSL Appendix 3B24/10/17
CSL Change of Director's Interest Notice20/10/17
CSL Final Director's Interest Notice Appendix 3Z18/10/17
CSL Results of 2017 Annual General Meeting18/10/17
CSL CEO's AGM PresentationPRICE SENSITIVE18/10/17
CSL Chairman's Address to Shareholders18/10/17
CSL New Debt FacilitiesPRICE SENSITIVE05/10/17
CSL Change to Company Details15/09/17
CSL FDA Approves Privigen for CIDP IndicationPRICE SENSITIVE15/09/17
CSL Retirement of Director15/09/17
CSL Annual Report to Shareholders15/09/17
CSL Notice of AGM/Proxy Form & Shareholder Questions15/09/17
CSL Appendix 4G - Key to Disclosures15/09/17
CSL Appendix 3B (Amended)13/09/17
CSL Appendix 3B12/09/17
CSL Final share buy-back notice - Appendix 3F05/09/17
CSL Final share buy-back notice - Appendix 3F05/09/17
CSL Daily share buy-back notice - Appendix 3E05/09/17
CSL Daily share buy-back notice - Appendix 3E04/09/17
CSL Change of Director's Interest Notice01/09/17
CSL Daily share buy-back notice - Appendix 3E01/09/17
CSL Daily share buy-back notice - Appendix 3E31/08/17
CSL Daily share buy-back notice - Appendix 3E30/08/17
CSL CSL Behring Acquires US Biotech Company CalimmunePRICE SENSITIVE28/08/17
CSL 2017 FY Results Announcement and Analysts PresentationPRICE SENSITIVE16/08/17
CSL Dividend/Distribution - CSL16/08/17
CSL Appendix 4E, Directors Report and Financial StatementsPRICE SENSITIVE16/08/17
CSL Notice of Investor/Analyst Briefing - 2017 Full Year Result10/08/17
CSL Change to Company Details04/08/17
CSL CSL Completes Acquisition of Majority Stake in RuidePRICE SENSITIVE03/08/17
CSL Change to Company Details17/07/17
CSL Daily share buy-back notice - Appendix 3E12/07/17
CSL Daily share buy-back notice - Appendix 3E11/07/17
CSL CSL Response to Patent Infringement ComplaintPRICE SENSITIVE10/07/17
CSL Daily share buy-back notice - Appendix 3E10/07/17
CSL Daily share buy-back notice - Appendix 3E07/07/17
CSL Daily share buy-back notice - Appendix 3E06/07/17
CSL Daily share buy-back notice - Appendix 3E05/07/17
CSL Daily share buy-back notice - Appendix 3E04/07/17
CSL CSL Shareholders Pack 2019
06/09/19
CSL Appendix 4G
06/09/19
CSL Notice of 2020 Dividend and AGM Dates
06/09/19
CSL CSL Notice of 2019 Annual General Meeting
06/09/19
CSL CSL Annual Report 2018/19
06/09/19
CSL Appendix 3B
12/03/19
CSL Change of Director's Interest Notice
21/02/19
CSL Update - Dividend/Distribution - CSL
20/02/19
CSL Appendix 3B
19/02/19
CSL Dividend/Distribution - CSL
13/02/19
CSL Half Year Results Analyst Presentation
13/02/19PRICE SENSITIVE
CSL Appendix 4D and Half Year Accounts
13/02/19PRICE SENSITIVE
CSL Notice of Investor/Analyst Briefing - Half Year Results 2019
06/02/19
CSL Appendix 3B
29/01/19
CSL 2019 JP Morgan Healthcare Conference
10/01/19
CSL CSL R&D Investor Briefing
05/12/18PRICE SENSITIVE
CSL Notice of Research & Development Investor Briefing
30/11/18
CSL Becoming a substantial holder
05/11/18
CSL Change of Director's Interest Notice
01/11/18
CSL Final Director's Interest Notice
22/10/18
CSL Final Director's Interest Notice
22/10/18
CSL Initial Director's Interest Notice
22/10/18
CSL Change of Director's Interest Notice
19/10/18
CSL Results of Meeting
17/10/18
CSL CSL Chairmans Address and CEOs Presentation
17/10/18
CSL Appendix 3B
25/09/18
CSL Change of Director's Interest Notice
21/09/18
CSL Appendix 4G - Key to Disclosures
14/09/18
CSL CSL Annual Report to shareholders
14/09/18
CSL Notice of Annual General Meeting/Proxy Form
14/09/18
CSL Change of Director's Interest Notice
07/09/18
CSL Appendix 3B
04/09/18
CSL Change of Director's Interest Notice
27/08/18
CSL Notice of Annual General Meeting
24/08/18
CSL Change of Director's Interest Notice
17/08/18
CSL Full Year Results Presentation
15/08/18
CSL Full Year Results Announcement
15/08/18PRICE SENSITIVE
CSL Dividend/Distribution - CSL
15/08/18
CSL Full Year Statutory Accounts
15/08/18PRICE SENSITIVE
CSL Notice of Investor and Analyst Briefing 2018 FY Results
08/08/18
CSL Appendix 3B
03/07/18
CSL Appendix 3B
22/05/18
CSL CSL Lifts Profit Guidance
18/05/18PRICE SENSITIVE
CSL Change of Director's Interest Notice
10/05/18
CSL Appointment of Company Secretary
19/04/18
CSL Appendix 3B
20/03/18
CSL Appendix 3B
27/02/18
CSL Change of Director's Interest Notice
16/02/18
CSL Initial Director's Interest Notice
16/02/18
CSL Initial Director's Interest Notice
16/02/18
CSL Half Year Results Analyst Presentation
14/02/18
CSL Dividend/Distribution - CSL
14/02/18
CSL Appendix 4D and Half Year Accounts
14/02/18PRICE SENSITIVE
CSL Notice of Investor/Analyst Briefing - 2018 Half Year Results
06/02/18
CSL Company Secretary Appointment/Resignation
21/12/17
CSL CSL Appoints New Directors
13/12/17
CSL Appendix 3B
05/12/17
CSL R&D Investor Briefing
05/12/17
CSL PGC: Acquisition of Immunohaematology Business
01/12/17PRICE SENSITIVE
CSL Notice of Research & Development Investor Briefing
30/11/17
CSL Appendix 3B
14/11/17
CSL Appendix 3B
24/10/17
CSL Change of Director's Interest Notice
20/10/17
CSL Final Director's Interest Notice Appendix 3Z
18/10/17
CSL Results of 2017 Annual General Meeting
18/10/17
CSL CEO's AGM Presentation
18/10/17PRICE SENSITIVE
CSL Chairman's Address to Shareholders
18/10/17
CSL New Debt Facilities
05/10/17PRICE SENSITIVE
CSL Change to Company Details
15/09/17
CSL FDA Approves Privigen for CIDP Indication
15/09/17PRICE SENSITIVE
CSL Retirement of Director
15/09/17
CSL Annual Report to Shareholders
15/09/17
CSL Notice of AGM/Proxy Form & Shareholder Questions
15/09/17
CSL Appendix 4G - Key to Disclosures
15/09/17
CSL Appendix 3B (Amended)
13/09/17
CSL Appendix 3B
12/09/17
CSL Final share buy-back notice - Appendix 3F
05/09/17
CSL Final share buy-back notice - Appendix 3F
05/09/17
CSL Daily share buy-back notice - Appendix 3E
05/09/17
CSL Daily share buy-back notice - Appendix 3E
04/09/17
CSL Change of Director's Interest Notice
01/09/17
CSL Daily share buy-back notice - Appendix 3E
01/09/17
CSL Daily share buy-back notice - Appendix 3E
31/08/17
CSL Daily share buy-back notice - Appendix 3E
30/08/17
CSL CSL Behring Acquires US Biotech Company Calimmune
28/08/17PRICE SENSITIVE
CSL 2017 FY Results Announcement and Analysts Presentation
16/08/17PRICE SENSITIVE
CSL Dividend/Distribution - CSL
16/08/17
CSL Appendix 4E, Directors Report and Financial Statements
16/08/17PRICE SENSITIVE
CSL Notice of Investor/Analyst Briefing - 2017 Full Year Result
10/08/17
CSL Change to Company Details
04/08/17
CSL CSL Completes Acquisition of Majority Stake in Ruide
03/08/17PRICE SENSITIVE
CSL Change to Company Details
17/07/17
CSL Daily share buy-back notice - Appendix 3E
12/07/17
CSL Daily share buy-back notice - Appendix 3E
11/07/17
CSL CSL Response to Patent Infringement Complaint
10/07/17PRICE SENSITIVE
CSL Daily share buy-back notice - Appendix 3E
10/07/17
CSL Daily share buy-back notice - Appendix 3E
07/07/17
CSL Daily share buy-back notice - Appendix 3E
06/07/17
CSL Daily share buy-back notice - Appendix 3E
05/07/17
CSL Daily share buy-back notice - Appendix 3E
04/07/17
(20min delay)
Last
$277.01
Change
-7.040(2.48%)
Mkt cap ! $142.5B
Open High Low Value Volume
$280.67 $281.07 $275.01 $254.8M 915.5K

Buyers (Bids)

No. Vol. Price($)
13 1140 $277.00
 

Sellers (Offers)

Price($) Vol. No.
$277.08 312 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
Last
$277.26
  Change
-7.040 ( 2.70 %)
Open High Low Volume
$280.95 $280.98 $275.02 88510
Last updated 15.59pm 15/11/2024 ?
CSL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.